Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 44

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 44
---
of and incorporated by reference into this prospectus supplement.

Unless the context requires otherwise, references in this
prospectus supplement to “Mirum,” “the company,” “we,” “us,” “our” or similar terms refer to Mirum Pharmaceuticals, Inc. and, where appropriate, our subsidiaries.

Company Overview

We are a
biopharmaceutical company dedicated to transforming the treatment of rare diseases. We have three approved medicines: LIVMARLI (maralixibat) (“Livmarli”), CHOLBAM (cholic acid) capsules (“Cholbam”), and CHENODAL or CTEXLI
(chenodiol) tablets (“Chenodal” or “Ctexli”).

Livmarli is a novel, orally administered, minimally-absorbed ileal bile
acid transporter (“IBAT”) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (“ALGS”) in the United States (“U.S.”), the European Union (“EU”) and various
other countries around the world and for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (“PFIC”) in the U.S. and for the treatment of PFIC in the EU. We market and commercialize Livmarli in the U.S.,
Canada and certain countries in Europe through our specialized and focused commercial team. We have also entered into license and distribution agreements with several rare disease companies for the commercialization of Livmarli in additional
countries. In March 2025, our partner, Takeda Pharmaceutical Company Limited, received approval by the Japanese Ministry of Health, Labour, and Welfare for Livmarli for the treatment of cholestatic pruritus in patients with ALGS and PFIC.

On October 22, 2024, we completed a license agreement with Enthorin Therapeutics, LLC and Dart Neuroscience LLC granting us the worldwide
right to develop and commercialize MRM-3379, an allosteric inhibitor of Phosphodiasterase 4d. We intend to develop MRM-3379 for the treatment of Fragile-X Syndrome and expect to initiate a Phase 2 clinical trial in 2025.

On August 31, 2023, we
completed the acquisition of assets of Travere Therapeutics, Inc. that are primarily related to the development, manufacture (including synthesis, formulation, finishing or packaging) and commercialization of chenodiol and Chol